Obi Pharma News Today

Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally. She brings a wealth... | June 2, 2023

Outrageously, against the fda. whats really fascinating abou this is it undermines decade of fta precedent its important for folks t understand bigger ramifications tha abortion rights, thats what m organization focuses on, thi could undermine the entire fda system, its authority, and thats why were seeing bi pharma, the a.m.a., and a lo of other organizations jumping into this case >> first i come fo mifepristone, what medicatio is next? >> what else was politically challenging. >> the covid va...

Abortion rights. although that is what my organization that focuses on this could undermine the entir fda that system. thats why were seeing bi pharma, the a.m.a., and a lo of the organizations jumping into this case >> and so richard, the nex steps in this case, it will go to the fifth circuit where a judge panel, we dont know who those judges are just yet, but they will hear the merits of the case they are going to take it into the law. they will issue their fina judgment on just his ruling. s...

OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 Combination Synergy with Checkpoint Inhibitor as well as Globo H-targeted CAR T-cell Immunotherapy

/PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174) today announced scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab...

/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...

/PRNewswire/ -- OBI Pharma, Inc. (OBI), a Taiwan biopharma company (TPEx: 4174), and Odeon Therapeutics (Odeon), a China biopharma company, have entered into...

/PRNewswire/ -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the first patients have been enrolled in both of the Phase 2 studies...

Second home-grown candidate does not trigger enough antibodies, according to regulator.